Iovance Biotherapeutics Inc (IOVA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Sales | 263,502 | 164,070 | 1,189 | 0 | 0 |
| Cost of Goods | 173,184 | 93,248 | 1,033 | N/A | N/A |
| Gross Profit | 90,318 | 70,822 | 156 | N/A | N/A |
| Operating Expenses | 493,858 | 466,348 | 460,748 | 398,878 | 342,703 |
| Operating Income | -403,356 | -395,278 | -460,559 | -398,878 | -342,703 |
| Other Income | 10,307 | 20,273 | 13,043 | 2,985 | 451 |
| Pre-tax Income | -393,049 | -375,005 | -447,516 | -395,893 | -342,252 |
| Income Tax | -2,071 | -2,828 | -3,479 | N/A | N/A |
| Net Income Continuous | -390,978 | -372,177 | -444,037 | -395,893 | -342,252 |
| Net Income | $-390,978 | $-372,177 | $-444,037 | $-395,893 | $-342,252 |
| EPS Basic Total Ops | -1.09 | -1.28 | -1.89 | -2.49 | -2.23 |
| EPS Basic Continuous Ops | -1.09 | -1.28 | -1.89 | -2.49 | -2.23 |
| EPS Diluted Total Ops | -1.09 | -1.28 | -1.89 | -2.49 | -2.23 |
| EPS Diluted Continuous Ops | -1.09 | -1.28 | -1.89 | -2.49 | -2.23 |
| EPS Diluted Before Non-Recurring Items | N/A | -1.28 | -1.89 | -2.49 | -2.23 |
| EBITDA(a) | $-363,234 | $-357,468 | $-431,037 | $-377,269 | $-322,710 |